Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab

Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy

NCT01804712 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

NCT05788081 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma

NCT01830465 ·Status: COMPLETED ·Phase: PHASE2

Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)

NCT02038946 ·Status: COMPLETED ·Phase: PHASE2

Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

NCT00176475 ·Status: TERMINATED ·Phase: PHASE1

Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

NCT00594815 ·Status: COMPLETED ·Phase: NA

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

NCT03927105 ·Status: COMPLETED ·Phase: PHASE2

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

NCT03623854 ·Status: COMPLETED ·Phase: PHASE2

Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma

NCT00039195 ·Status: COMPLETED ·Phase: PHASE2

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

NCT02535286 ·Status: COMPLETED ·Phase: PHASE1

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

NCT03361852 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

NCT03169790 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma

NCT00003605 ·Status: WITHDRAWN ·Phase: PHASE2

Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma

NCT00134082 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

NCT04416451 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

NCT00031902 ·Status: UNKNOWN ·Phase: PHASE1

Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma

NCT00005631 ·Status: COMPLETED ·Phase: PHASE2

Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease

NCT00136396 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

NCT00193492 ·Status: COMPLETED ·Phase: PHASE2

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

NCT02631746 ·Status: COMPLETED ·Phase: PHASE2

Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma

NCT02204982 ·Status: TERMINATED ·Phase: PHASE3

Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma

NCT00227695 ·Status: COMPLETED ·Phase: PHASE3

Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A

NCT03245021 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

NCT00010192 ·Status: COMPLETED ·Phase: PHASE1

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

NCT03919175 ·Status: TERMINATED ·Phase: PHASE2